Mr. Chair, I want to thank the member for her question.
Our approach has been very clear when it comes to science. We have an open science model, and we're working with different partners and different jurisdictions to help develop vaccines and look at countermeasures and other therapeutics. Our goal is to make sure that we do so in a collaborative fashion, because this is a global pandemic, but make no mistake: If it's Canadian ingenuity and Canadian IP that's driving it, we want to support them as well.